NetraMark Holdings Inc. announced that it has signed a fourth contract in a new indication with a large, publicly listed biopharmaceutical company, pursuant to the Master Service Agreement, previously announced on October 23, 2023. NetraMark will employ its proprietary NetraAI to analyze clinical trial data from the biopharmaceutical company's late phase asset and the primary objectives of the contract are as follows: Perform an analysis with the NetraAI based on variables derived from pertinent factors collected between screening and baseline. Generate subpopulation personas that show significant differences between responders and non-responders.

Provide a set of features that can be used for exclusion/inclusion criteria for the pivotal trial, if necessary. Characterize subsets of patients who experience adverse effects (AEs), if any, with the resulting personas used to mitigate safety concerns in future trials.